The DOI matches its Crossref record; 314 of the 314 references it cites were found in a registry or an index.
Antibiotics and Bacterial Resistance in the 21st Century
Open accessAbstract
Dangerous, antibiotic resistant bacteria have been observed with increasing frequency over the past several decades. In this review the factors that have been linked to this phenomenon are addressed. Profiles of bacterial species that are deemed to be particularly concerning at the present time are illustrated. Factors including economic impact, intrinsic and acquired drug resistance, morbidity and mortality rates, and means of infection are taken into account. Synchronously with the waxing of bacterial resistance there has been waning antibiotic development. The approaches that scientists are employing in the pursuit of new antibacterial agents are briefly described. The standings of established antibiotic classes as well as potentially emerging classes are assessed with an emphasis on molecules that have been clinically approved or are in advanced stages of development. Historical perspectives, mechanisms of action and resistance, spectrum of activity, and preeminent members of each class are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–314 of 314
Elemam, A., Rahimian, J., & Mandell, W. (2009) · Clinical Infectious Diseases · doi:10.1086/600042 · Cited by 156
Antibiotic resistance is ancient: implications for drug discovery
Wright, G. D., & Poinar, H. N. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.01.002 · Cited by 154
Naas, T., & Nordmann, P. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230112185101 · Cited by 154
Locke, J. B., Finn, J., Hilgers, M. T., Morales, G., Rahawi, S., Kedar, G. C., Picazo, J. J., Im, W., Shaw, K. J., & Stein, J. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00663-10 · Cited by 153
Crespo, M., Woodford, N., Sinclair, A., Kaufmann, M. E., Turton, J. F., Glover, J., Vélez, J. D., Castañeda-Ramirez, C. R., Recalde, M. P., & Livermore, D. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.11.5094-5101.2004 · Cited by 153
Outpatient Use of Erythromycin: Link to Increased Erythromycin Resistance in Group A Streptococci
Seppälä, H., Klaukka, T., Lehtonen, R., NENONEN, E., Finnish Study Group for Antimicrobial Resistance, & Huovinen, P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.6.1378 · Cited by 152
Molecular Characterization of an Epidemic Clone of Panantibiotic-ResistantPseudomonas aeruginosa
Deplano, A., Denis, O., Poirel, L., Hocquet, D., Nonhoff, C., Byl, B., Nordmann, P., Vincent, J., & Struelens, M. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.3.1198-1204.2005 · Cited by 146
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
Needham, J., Kelly, M. T., Ishige, M., & Andersen, R. J. (1994) · The Journal of Organic Chemistry · doi:10.1021/jo00087a020 · Cited by 139
Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents
Vaara, M., Fox, J., Loidl, G., Siikanen, O., Apajalahti, J., Hansen, F., Frimodt‐Møller, N., Nagai, J., Takano, M., & Vaara, T. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00405-08 · Cited by 138
Khokhlov, A. S., Tovarova, I. I., Ln, B., Pliner, S. A., Shevchenko, L. N., Kornitskaia, E. I., Ns, I., & Rapoport, I. A. (1970) · PubMed · Cited by 137
Acinetobacter baumannii:an emerging multidrug-resistant threat
Gootz, T. D., & Marra, A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.3.309 · Cited by 134
The discovery of antibacterial agents using diversity-oriented synthesis
Galloway, W. R. J. D., Bender, A., Welch, M., & Spring, D. R. (2009) · Chemical Communications · doi:10.1039/b816852k · Cited by 133
Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance
Pokrovskaya, V., & Baasov, T. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.508069 · Cited by 132
Overcoming antimicrobial resistance by targeting resistance mechanisms
Poole, K. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775514 · Cited by 129
Poirel, L., Girlich, D., Naas, T., & Nordmann, P. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.447-453.2001 · Cited by 129
Depardieu, F., & Courvalin, P. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.319-323.2001 · Cited by 128
Lolans, K., Queenan, A. M., Bush, K., Sahud, A., & Quinn, J. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3538-3540.2005 · Cited by 126
Yang, S., Kreiswirth, B. N., Sakoulas, G., Yeaman, M. R., Xiong, Y. Q., Sawa, A., & Bayer, A. S. (2009) · The Journal of Infectious Diseases · doi:10.1086/648473 · Cited by 126
Economics of antibiotic resistance
Sıpahı, O. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.4.523 · Cited by 125
Plaza, A., Keffer, J. L., Bifulco, G., Lloyd, J. R., & Bewley, C. A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102100h · Cited by 124
2012 and beyond: potential for the start of a second pre-antibiotic era?
Appelbaum, P. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks213 · Cited by 124
Li, W., Leet, J. E., AX, H. A., GUSTAVSON, D. R., Brown, D. M., TURNER, L., BROWN, K., Clark, J. M., Yang, H., Fung-Tomc, J. C., et al. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.226 · Cited by 124
Sader, H. S., Rhomberg, P. R., Farrell, D. J., & Jones, R. N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01737-10 · Cited by 123
Glycopeptides: Update on an old successful antibiotic class
Pace, J., & Yang, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.005 · Cited by 122
Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland
Palmer, H. M., Young, H.-K., Winter, A., & Dave, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn235 · Cited by 117
Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications
Pallecchi, L., Bartoloni, A., Paradisi, F., & Rossolini, G. M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.725 · Cited by 115
Smith, L. K., & Mankin, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01583-07 · Cited by 115
Yong, M. K., Buising, K. L., Cheng, A. C., & Thursky, K. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq058 · Cited by 115
Impact of antibiotic restrictions: the pharmaceutical perspective
Power, E. E. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01528.x · Cited by 111
2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ
White, E. L., Suling, W. J., Ross, L. J., Seitz, L. E., & Reynolds, R. C. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf075 · Cited by 111
Hugo and Russell's Pharmaceutical Microbiology
Denyer, S. P., & Hugo, W. B. (2004) · Wiley eBooks · doi:10.1002/9780470988329 · Cited by 110
Payne, D. J., Hueso-Rodríguez, J. A., Boyd, H., Concha, N. O., Janson, C. A., Gilpin, M. L., Bateson, J. H., Cheever, C. A., Niconovich, N. L., Pearson, S. C., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1880-1886.2002 · Cited by 109
Haydon, D. J., Bennett, J. M., Brown, D., Collins, I., Galbraith, G., Lancett, P., Macdonald, R., Stokes, N. R., Chauhan, P. K., Sutariya, J. K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016366 · Cited by 106
Mazzariol, A., Cornaglia, G., & Nikaido, H. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1387-1390.2000 · Cited by 105
Activity of the Ketolide Telithromycin Is Refractory to Erm Monomethylation of Bacterial rRNA
Liu, M., & Douthwaite, S. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1629-1633.2002 · Cited by 104
Multiple effects of benzamide antibiotics on FtsZ function
Adams, D. W., Wu, L. J., Czaplewski, L. G., & Errington, J. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07559.x · Cited by 100
Improving known classes of antibiotics: an optimistic approach for the future
Bush, K. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.003 · Cited by 100
Queenan, A. M., Shang, W., Flamm, R. K., & Bush, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01004-09 · Cited by 99
Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains
Yang, S.-J., Xiong, Y. Q., Dunman, P. M., Schrenzel, J., François, P., Peschel, A., & Bayer, A. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01415-08 · Cited by 98
The antibiotic R&D pipeline: an update
Jabes, D. L. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.08.002 · Cited by 96
Strain improvement in actinomycetes in the postgenomic era
Baltz, R. H. (2011) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-010-0934-z · Cited by 96
Macrae, M. B., Shannon, K. P., Rayner, D., Kaiser, A. M., Hoffman, P. N., & French, G. L. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1066 · Cited by 95
Andes, D. R., Anon, J. B., Jacobs, M. R., et al. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.009 · Cited by 95
Schwendener, S., & Perreten, V. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00528-11 · Cited by 94
Medicinal Chemistry Optimization of Acyldepsipeptides of the Enopeptin Class Antibiotics
Hinzen, B., Raddatz, S., Paulsen, H., Lampe, T. F. J., Schumacher, A., Häbich, D., Hellwig, V., Benet‐Buchholz, J., Endermann, R., Labischinski, H., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600055 · Cited by 93
First Description of an Escherichia coli Strain Producing NDM-1 Carbapenemase in Spain
Solé, M., Pitart, C., Roca, I., Fàbrega, A., Salvador, P., Muñoz, L., Oliveira, I., Gascón, J., Marco, F., & Vilà, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00642-11 · Cited by 93
Bertsche, U., Yang, S., Kühner, D., Wanner, S., Mishra, N. N., Roth, T., Nega, M., Schneider, A. T., Mayer, C., Grau, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067398 · Cited by 92
Urgaonkar, S., Pierre, H. S. L., Meir, I., Lund, H., RayChaudhuri, D., & Shaw, J. T. (2005) · Organic Letters · doi:10.1021/ol052269z · Cited by 92
Treatment options for multidrug-resistant bacteria
Giamarellou, H. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.4.601 · Cited by 91
Antibiotics in development targeting protein synthesis
Sutcliffe, J. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06323.x · Cited by 89
Increased Antibiotic Resistance in Respiratory Tract Pathogens: PROTEKT US—An Update
Karchmer, A. W. (2004) · Clinical Infectious Diseases · doi:10.1086/421352 · Cited by 89
Panton-Valentine Leukocidin and Staphyloccoccal Skin Infections in Schoolchildren1
Boubaker, K., Diebold, P., Blanc, D., Vandenesch, F., Praz, G., Dupuis, G., & Troillet, N. (2004) · Emerging infectious diseases · doi:10.3201/eid1001.030144 · Cited by 86
Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium
Cooper, M. A., & Williams, D. H. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80008-3 · Cited by 85
Davlieva, M. G., Zhang, W., Arias, C. A., & Shamoo, Y. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01743-12 · Cited by 84
Adair, F. W., Geftic, S. G., & Gelzer, J. (1969) · Applied Microbiology · doi:10.1128/am.18.3.299-302.1969 · Cited by 83
Action of atrop‐Abyssomicin C as an Inhibitor of 4‐Amino‐4‐deoxychorismate Synthase PabB
Keller, S., Schadt, H. S., Ortel, I., & Süßmuth, R. D. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701836 · Cited by 80
Miller, K., Dunsmore, C. J., Fishwick, C. W. G., & Chopra, I. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01015-07 · Cited by 79
Are natural products still the best source for antibacterial discovery? The bacterial entry factor
Silver, L. L. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.5.487 · Cited by 78
Old antibiotics for infections in critically ill patients
Falagas, M. E., & Kopterides, P. (2007) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32827851d7 · Cited by 77
Enzymes as a special class of therapeutic target: clinical drugs and modes of action
Robertson, J. G. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.08.008 · Cited by 75
In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens
Lawrence, L. E., Danese, P. N., DeVito, J. A., Franceschi, F. J., & Sutcliffe, J. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01383-07 · Cited by 72
Kadlec, K., Pomba, C., Couto, N., & Schwarz, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq365 · Cited by 72
3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents
Kelley, C., Zhang, Y., Parhi, A. K., Kaul, M., Pilch, D. S., & LaVoie, E. J. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.10.009 · Cited by 70
Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
Kallen, A. J., & Srinivasan, A. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/655996 · Cited by 70
Antibiotics from microbes: converging to kill
Fischbach, M. A. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.07.002 · Cited by 68
Current concepts in antibiotic-resistant Gram-negative bacteria
Torres, J. A., Villegas, M. V., & Quinn, J. P. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.833 · Cited by 67
Ciprofloxacin-Resistant Gram-Negative Bacilli in the Fecal Microflora of Children
Qin, X. G., Razia, Y., Johnson, J. R., Stapp, J. R., Boster, D. R., Tsosie, T., Smith, D. L., Braden, C. R., Gay, K., Angulo, F. J., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00548-06 · Cited by 64
Russo, T. A., Page, M. G. P., Beanan, J. M., Olson, R., Hujer, A. M., Hujer, K. M., Jacobs, M. R., Bajaksouzian, S., Endimiani, A., & Bonomo, R. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr013 · Cited by 63
Fritsche, T. R., Sader, H. S., Cleeland, R., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1468-1476.2005 · Cited by 62
Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis
Wyatt, E. E., Galloway, W. R. J. D., Thomas, G. L., Welch, M., Loiseleur, O., Plowright, A. T., & Spring, D. R. (2008) · Chemical Communications · doi:10.1039/b812901k · Cited by 59
Higgins, P. G., Stubbings, W., Wisplinghoff, H., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01637-09 · Cited by 59
Resistance phenotypes conferred by macrolide phosphotransferases
Chesneau, O., Tsvetkova, K., & Courvalin, P. M. (2007) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.00643.x · Cited by 58
Will new antimicrobials overcome resistance among Gram-negatives?
Bassetti, M., Ginocchio, F., Mikulska, M., Taramasso, L., & Giacobbe, D. R. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.107 · Cited by 58
Screening strategies for discovery of antibacterial natural products
Singh, S. B., Young, K., & Miesel, L. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.81 · Cited by 56
In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698
Lofland, D. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh129 · Cited by 54
Novel therapeutic strategies to counterPseudomonas aeruginosainfections
Fothergill, J. L., Winstanley, C., & James, C. E. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.168 · Cited by 52
Structure-Based Phylogenies of the Serine ?-Lactamases
Hall, B. G., & Barlow, M. (2003) · Journal of Molecular Evolution · doi:10.1007/s00239-003-2473-y · Cited by 51
Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship
Jacob, J. T., & Gaynes, R. P. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.73 · Cited by 49
Putnam, S. D., Sader, H. S., Farrell, D. J., Biedenbach, D. J., & Castanheira, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.021 · Cited by 48
Whole-Animal High-Throughput Screens: The C. elegans Model
O’Rourke, E. J., Conery, A. L., & Moy, T. I. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-545-3_5 · Cited by 46
Update on prevalence and treatment of methicillin-resistantStaphylococcus aureusinfections
Loffler, C. A., & MacDougall, C. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.6.961 · Cited by 45
Rodloff, A. C., Leclercq, R., Debbia, E. A., Cantón, R., Oppenheim, B. A., & Dowzicky, M. J. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01943.x · Cited by 44
Moore, P. B., & Steitz, T. A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.04.006 · Cited by 44
Antibacterial activity of substituted 5-methylbenzo[c]phenanthridinium derivatives
Parhi, A. K., Kelley, C., Kaul, M., Pilch, D. S., & LaVoie, E. J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.097 · Cited by 43
Hornsey, M., Ellington, M. J., Doumith, M., Hudson, S., Livermore, D. M., & Woodford, N. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp475 · Cited by 43
Edelstein, P. H. (2004) · Clinical Infectious Diseases · doi:10.1086/382687 · Cited by 43
Ruzin, A. V., Immermann, F. W., & Bradford, P. A. (2010) · Microbial Drug Resistance · doi:10.1089/mdr.2009.0131 · Cited by 41
Speculative strategies for new antibacterials: all roads should not lead to Rome
Shapiro, S. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.27 · Cited by 41
Novel β-lactam antibiotics and inhibitor combinations
Bassetti, M., Righi, E., & Viscoli, C. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.285 · Cited by 41
Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells
Mingeot‐Leclercq, M., Tulkens, P. M., Denamur, S., Vaara, T., & Vaara, M. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.033 · Cited by 41
Quale, J. M., Shah, N., Kelly, P., Babu, E., Bäcker, M., Rosas-Garcia, G., Salamera, J., George, A., Bratu, S., & Landman, D. (2011) · Microbial Drug Resistance · doi:10.1089/mdr.2011.0163 · Cited by 39
Gemmacin B: bringing diversity back into focus
Robinson, A., Thomas, G. L., Spandl, R. J., Welch, M., & Spring, D. R. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b809038f · Cited by 37
The search for new antimicrobials: why we need new options
Zinner, S. H. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.6.907 · Cited by 35
Roles of Salmonella multidrug efflux pumps in tigecycline resistance
Horiyama, T., Nikaido, E., Yamaguchi, A., & Nishino, K. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq421 · Cited by 35
PDF Inhibitors: An Emerging Class of Antibacterial Drugs
Johnson, K., Lofland, D., & Moser, H. E. (2005) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005053174618 · Cited by 33
3 Peptide Deformylase Inhibitors
Aubart, K. M., & Zalacaín, M. (2006) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(05)44403-3 · Cited by 32
Lin, G., Ednie, L. M., & Appelbaum, P. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01350-09 · Cited by 31
Vaara, M., Sader, H. S., Rhomberg, P. R., Jones, R., & Vaara, T. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks438 · Cited by 31
Oritavancin: a new avenue for resistant Gram-positive bacteria
Mercier, R.-C., & Hrebickova, L. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.3.325 · Cited by 31
Anonymous, C. (2008) · Eurosurveillance · doi:10.2807/ese.13.46.19035-en · Cited by 30
The use of platensimycin and platencin to fight antibiotic resistance
Allahverdiyev, A., BAGIROVA, Ateş, S. C., Çakır-Koç, R., Miraloğlu, M., Elçıçek, S., Yaman, S., Unal, G., & Abamor, E. Ş. (2013) · Infection and Drug Resistance · doi:10.2147/idr.s25076 · Cited by 28
Ceftobiprole: a new broad spectrum cephalosporin
Solh, A. A. E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903048967 · Cited by 28
Şentürk, S. (2005) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00634.x · Cited by 27
Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2
Morrow, B. J., Abbanat, D., Baum, E. Z., Crespo‐Carbone, S. M., Davies, T. A., He, W., Shang, W., Queenan, A. M., & Lynch, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00470-11 · Cited by 27
Jemni, L., Hmouda, H., & Letaief, A. O. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.1.202 · Cited by 25
Goldstein, E. J. C., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02580-12 · Cited by 24
Cipolla, L., Polissi, A., Airoldi, C., Galliani, P., Sperandeo, P., & Nicotra, F. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581093 · Cited by 24
Substituted 1,6-diphenylnaphthalenes as FtsZ-targeting antibacterial agents
Zhang, Y., Giurleo, D. J., Parhi, A. K., Kaul, M., Pilch, D. S., & LaVoie, E. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.016 · Cited by 19
Antimycobacterial spectrum of colistin (polymixin E)
Rastogi, N., Blom-Potar, M.-C., & David, H. L. (1986) · Research in Microbiology · doi:10.1016/s0769-2609(86)80004-7 · Cited by 18
Witting, K. F., & Süßmuth, R. D. (2011) · Current Drug Targets · doi:10.2174/138945011798109527 · Cited by 13
Fisher, M., Basak, R., Kalverda, A. P., Fishwick, C. W. G., Turnbull, W. B., & Nelson, A. S. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41975d · Cited by 12
Rifaximin: recent advances in gastroenterology and hepatology.
Lichtenstein, G. R. (2007) · Europe PMC (PubMed Central) · Cited by 2
Cited by
Singh, J., Dutta, T., Kim, K.-H., Rawat, M., Samddar, P., & Kumar, P. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0408-4 · Cited by 2,700
Antibiotic resistance: a rundown of a global crisis
Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173867 · Cited by 2,552
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.014 · Cited by 1,212
Li, B., & Webster, T. J. (2018) · Journal of Orthopaedic Research · doi:10.1002/jor.23656 · Cited by 907
Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019) · Metabolites · doi:10.3390/metabo9110258 · Cited by 867
Metadata
- Authors
- Fair, R. J., & Tor, Y.
- Venue
- Perspectives in Medicinal Chemistry
- Publisher
- SAGE Publications
- Published
- 2014-01
- Volume
- 6
- Pages
- 25-64
- ISSN
- 1177-391X (ISSN-L)
- OpenAlex
- W2009933778
- Cited by
- 1,955
- References
- 314
- FWCI
- 24.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.